-
Mashup Score: 0Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission - 8 hour(s) ago
Molecular MRD after induction chemotherapy identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.Patients achieving M
Source: ashpublications.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 28LinkedIn - 4 day(s) ago
This link will take you to a page that’s not on LinkedIn
Source: lnkd.inCategories: General Medicine News, Hematologists1Tweet-
FREE!!!May 24th👇👇👇 JORNADA DE ACTUALIZACIÓN EN TRASPLANTE DE PROGENITORES HEMATOPOYÉTICOS (TPH): oportunidades para el equipo multidisciplinar🩸 @ICO_oncologia @HematICO_Hosp In-person & Online! links to course registration https://t.co/jsmvASHApG https://t.co/VASY0dqFBZ https://t.co/jcxr6TPgvh
-
-
Mashup Score: 1ByteMed#4: Diagnosing Mendelian disorders and Leukemia subtype with AI, reducing mortality with AI ECG interpretation - 11 day(s) ago
AI-MARRVEL — A Knowledge-Driven AI System for Diagnosing Mendelian Disorders BACKGROUND Diagnosing genetic disorders requires extensive manual curation and interpretation of candidate variants, a labor-intensive task even for trained geneticists. Although artificial intelligence (AI) shows promise in aiding these diagnoses, existing AI tools have only achieved moderate success for primary diagnosis.
Source: albertomussetti.substack.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 17Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML - 13 day(s) ago
PURPOSE Crenolanib is a second-generation tyrosine kinase inhibitor with activity against FLT3-ITD– and TKD-mutant AML. We conducted a trial of crenolanib plus intensive chemotherapy in adults with newly diagnosed FLT3-mutant AML. METHODS Eligible patients were 18 years and older. Induction chemotherapy consisted of cytarabine (100 mg/m2) continuous infusion on days 1-7 and anthracycline (daunorubicin 60-90 mg/m2 or idarubicin 12 mg/m2, once daily) on days 1-3 followed by consolidation with high-dose cytarabine (1-3 g/m2 twice daily on days 1, 3, 5) and/or allogeneic transplant. Crenolanib (100 mg thrice a day) was given from day 9 until 72 hours before the next cycle, after consolidation, and for 12 months after consolidation or transplant. RESULTS Forty-four patients (median age, 57; range, 19-75 years) were enrolled. Thirty-six had FLT3-ITD, and 11 had FLT3-TKD mutations. European LeukemiaNet 2017 disease risk was favorable in 34%, intermediate in 30%, and adverse in 36%. The overal
Source: ascopubs.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 0ByteMed #3: AI in healthcare roadmap, 700.000 wearbale data and GPT4 better than residents - 25 day(s) ago
The algorithm journey map: a tangible approach to implementing AI solutions in healthcare When integrating AI tools in healthcare settings, complex interactions between technologies and primary users are not always fully understood or visible. This deficient and ambiguous understanding hampers attempts by healthcare organizations to adopt AI/ML, and it also creates new challenges for researchers to identify opportunities for simplifying adoption and developing best practices for the use of AI-based solutions. Our study fills this gap by documenting the process of designing, building, and maintaining an AI solution called SepsisWatch at Duke University Health System. We conducted 20 interviews with the team of engineers and scientists that led the multi-year effort to build the tool, integrate it into practice, and maintain the solution. This “Algorithm Journey Map” enumerates all social and technical activities throughout the AI solution’s procurement, development, integration, and ful
Source: albertomussetti.substack.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 26
PURPOSE Recurrence of blood malignancy is the major cause of hematopoietic cell transplant failure. HLA class II molecules play a fundamental role in antitumor responses but the role of class II haplotypes is not known. METHODS HLA-DR, -DQ, -DM, and -DO allele variation was determined in 1,629 related haploidentical transplants to study the clinical significance of individual molecules and haplotypes. RESULTS Outcome correlated with patient and donor variation for HLA-DRβ residue 86 (Gly/Val), HLA-DQ (G1/G2) heterodimers, and donor HLA-DM (DM11,11/nonDM11,11) molecules, and depended on patient-donor mismatching. Risks of relapse were lower for DRβ-86 GlyGly patients when the donor was GlyVal (hazard ratio [HR], 0.46 [95% CI, 0.30 to 0.68]; P < .001); GlyVal patients benefited from HLA-DRB1–matched donors, whereas no donor was superior to another for ValVal patients. G1G2 patients with G1G2-mismatched donors had lower relapse. Transplantation from donors with DMα residue 184 ArgHis was
Source: ascopubs.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 0ByteMed #2: AI Roadmap, GPT4 in cancer center and machine learning preaasessment for pre-eclampsia - 1 month(s) ago
The AI Maturity Roadmap: A Framework for Effective and Sustainable AI in Health Care Thanks for reading ByteMed – AI and Medicine! Subscribe for free to receive new posts and support my work. BACKGROUND Though many health systems are starting to deploy artificial intelligence (AI) and machine learning for clinical applications, there is limited guidance available to benchmark progress and assess maturity on a sector-wide scale.
Source: albertomussetti.substack.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 2ByteMed #2: AI Roadmap, GPT4 in cancer center and machine learning preaasessment for pre-eclampsia - 1 month(s) ago
The AI Maturity Roadmap: A Framework for Effective and Sustainable AI in Health Care Thanks for reading ByteMed – AI and Medicine! Subscribe for free to receive new posts and support my work. BACKGROUND Though many health systems are starting to deploy artificial intelligence (AI) and machine learning for clinical applications, there is limited guidance available to benchmark progress and assess maturity on a sector-wide scale.
Source: albertomussetti.substack.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 41How I reduce and treat posttransplant relapse of MDS - 1 month(s) ago
Posttransplant relapse is the major cause of failure when patients undergo allogeneic stem cell transplant as a cure for myelodysplastic syndromes (MDS). M
Source: ashpublications.orgCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 13CD70-specific CAR-NK cells expressing IL-15 for the treatment of CD19-negative B cell malignancy - 1 month(s) ago
Key Points. CD70-specific CAR-NK cells secrete IL-15, specifically lyse both CD19 positive and CD19 negative B cell lymphoma in vitro and in vivoTwo doses
Source: ashpublications.orgCategories: General Medicine News, Hematologists1Tweet
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission https://t.co/e2EHO3s8lx